Tags

Type your tag names separated by a space and hit enter

COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform.
Biomed Res Int. 2021; 2021:6658070.BR

Abstract

In light of the devastation caused by COVID-19, the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and vaccine research and development (R&D) have been occupying a prominent position in the field of global health diplomacy (GHD). Most countries, international organizations, and charitable organizations have been engaged in the R&D of COVID-19 vaccines to ensure timely affordability and accessibility to all countries. Concomitantly, the World Trade Organization (WTO) provides some provisions and enforcements regarding copyrights, patents, trademarks, geographical indications, and industrial designs. Given these safeguards, it is considered that intellectual property rights (IPRs) have become major barriers to the affordability and accessibility of vaccines/medicines/technology, particularly to the developing/least developed countries. Realizing the gravity of the pandemic impact, as well as its huge population and size, India has elevated this issue in its global health diplomacy by submitting a joint proposal with South Africa to the World Trade Organization (WTO) for a temporary waiver of IPRs to ensure timely affordability and accessibility of COVID-19 medical products to all countries. However, the issue of the temporary waive off had become a geopolitical issue. Countries that used to claim per se as strong advocates of human rights, egalitarianism, and healthy democracy have opposed this proposal. In this contrasting milieu, this paper is aimed at examining how the TRIPS has become a barrier for developing countries' development and distribution of vaccines/technology; secondly, how India strategizes its role in the WTO in pursuant of its global health diplomacy? We conclude that the IPRs regime should not become a barrier to the accessibility/affordability of essential drugs and vaccines. To ensure access, India needs to get more engaged in GHD with all the involved global stakeholders to get strong support for their joint proposal. The developed countries that rejected/resisted the proposal can rethink their full support.

Authors+Show Affiliations

Division of Occupational Medicine, Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada M5G 2C4. Department of Public Health, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, 600077, Chennai, India. Institute of International Relations, The University of the West Indies, St. Augustine, Trinidad and Tobago.Department of South and Central Asian Studies, School of International Studies, Central University of Punjab, PIN-151401, Bathinda, India.Department of law, Guru Nanak Dev University, Regional Campus, Jalandhar, Punjab 144007, India.Department of Global Health Economics and Policy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia. Institute of Comparative Economics, Hosei University, Tokyo 194-0298, Japan. Department of Public Health and Healthcare named after N.A. Semashko I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

34485525

Citation

Chattu, Vijay Kumar, et al. "COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform." BioMed Research International, vol. 2021, 2021, p. 6658070.
Chattu VK, Singh B, Kaur J, et al. COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform. Biomed Res Int. 2021;2021:6658070.
Chattu, V. K., Singh, B., Kaur, J., & Jakovljevic, M. (2021). COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform. BioMed Research International, 2021, 6658070. https://doi.org/10.1155/2021/6658070
Chattu VK, et al. COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform. Biomed Res Int. 2021;2021:6658070. PubMed PMID: 34485525.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform. AU - Chattu,Vijay Kumar, AU - Singh,Bawa, AU - Kaur,Jaspal, AU - Jakovljevic,Mihajlo, Y1 - 2021/08/26/ PY - 2020/12/05/received PY - 2021/03/19/revised PY - 2021/08/12/accepted PY - 2021/9/6/entrez PY - 2021/9/7/pubmed PY - 2021/9/15/medline SP - 6658070 EP - 6658070 JF - BioMed research international JO - Biomed Res Int VL - 2021 N2 - In light of the devastation caused by COVID-19, the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and vaccine research and development (R&D) have been occupying a prominent position in the field of global health diplomacy (GHD). Most countries, international organizations, and charitable organizations have been engaged in the R&D of COVID-19 vaccines to ensure timely affordability and accessibility to all countries. Concomitantly, the World Trade Organization (WTO) provides some provisions and enforcements regarding copyrights, patents, trademarks, geographical indications, and industrial designs. Given these safeguards, it is considered that intellectual property rights (IPRs) have become major barriers to the affordability and accessibility of vaccines/medicines/technology, particularly to the developing/least developed countries. Realizing the gravity of the pandemic impact, as well as its huge population and size, India has elevated this issue in its global health diplomacy by submitting a joint proposal with South Africa to the World Trade Organization (WTO) for a temporary waiver of IPRs to ensure timely affordability and accessibility of COVID-19 medical products to all countries. However, the issue of the temporary waive off had become a geopolitical issue. Countries that used to claim per se as strong advocates of human rights, egalitarianism, and healthy democracy have opposed this proposal. In this contrasting milieu, this paper is aimed at examining how the TRIPS has become a barrier for developing countries' development and distribution of vaccines/technology; secondly, how India strategizes its role in the WTO in pursuant of its global health diplomacy? We conclude that the IPRs regime should not become a barrier to the accessibility/affordability of essential drugs and vaccines. To ensure access, India needs to get more engaged in GHD with all the involved global stakeholders to get strong support for their joint proposal. The developed countries that rejected/resisted the proposal can rethink their full support. SN - 2314-6141 UR - https://www.unboundmedicine.com/medline/citation/34485525/COVID_19_Vaccine_TRIPS_and_Global_Health_Diplomacy:_India's_Role_at_the_WTO_Platform_ L2 - https://doi.org/10.1155/2021/6658070 DB - PRIME DP - Unbound Medicine ER -